CL2017002482A1 - Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas - Google Patents
Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianasInfo
- Publication number
- CL2017002482A1 CL2017002482A1 CL2017002482A CL2017002482A CL2017002482A1 CL 2017002482 A1 CL2017002482 A1 CL 2017002482A1 CL 2017002482 A CL2017002482 A CL 2017002482A CL 2017002482 A CL2017002482 A CL 2017002482A CL 2017002482 A1 CL2017002482 A1 CL 2017002482A1
- Authority
- CL
- Chile
- Prior art keywords
- bacterial infections
- prevention
- heterocyclic compounds
- treatment
- compounds
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305508.2A EP3075381A1 (en) | 2015-04-03 | 2015-04-03 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP16305069 | 2016-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002482A1 true CL2017002482A1 (es) | 2018-04-20 |
Family
ID=55646608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002482A CL2017002482A1 (es) | 2015-04-03 | 2017-10-02 | Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10501481B2 (enExample) |
| EP (1) | EP3277277B1 (enExample) |
| JP (1) | JP2018510198A (enExample) |
| KR (1) | KR20170132316A (enExample) |
| CN (1) | CN107438614B (enExample) |
| AU (1) | AU2016239861A1 (enExample) |
| BR (1) | BR112017020935A2 (enExample) |
| CA (1) | CA2980395A1 (enExample) |
| CL (1) | CL2017002482A1 (enExample) |
| MX (1) | MX2017012545A (enExample) |
| RU (1) | RU2714197C2 (enExample) |
| TW (1) | TW201639854A (enExample) |
| WO (1) | WO2016156597A1 (enExample) |
| ZA (1) | ZA201706348B (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10717737B2 (en) | 2014-02-13 | 2020-07-21 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| US10968221B2 (en) | 2014-07-10 | 2021-04-06 | Incyte Corporation | Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US11155532B2 (en) | 2014-02-13 | 2021-10-26 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US11401272B2 (en) | 2015-04-03 | 2022-08-02 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
| US11498900B2 (en) | 2015-08-12 | 2022-11-15 | Incyte Corporation | Salts of an LSD1 inhibitor |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| JOP20190061A1 (ar) * | 2016-09-28 | 2019-03-26 | Novartis Ag | مثبطات بيتا-لاكتاماز |
| EP3300736B1 (en) * | 2016-09-30 | 2021-05-05 | Mutabilis | Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections |
| EP3357924A1 (en) | 2017-02-06 | 2018-08-08 | Mutabilis | Novel heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP3604315A1 (en) | 2018-07-30 | 2020-02-05 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| ES2960952T3 (es) | 2018-08-09 | 2024-03-07 | Antabio Sas | Diazabiciclooctanonas como inhibidores de serina beta-lactamasas |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1107541A1 (ru) * | 1982-12-03 | 1995-10-20 | Институт Тонкой Органической Химии Им.А.Л.Мнджояна | 10-нитро-1,6,8-триазатрицикло [6,3,1,1] тридекан-2,5-дион |
| ES2127946T3 (es) | 1993-12-29 | 1999-05-01 | Pfizer | Antagonistas de neurocinina diazabiciclica. |
| FR2825705B1 (fr) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| US20040009234A1 (en) * | 2002-07-10 | 2004-01-15 | Meisel Gerard M. | Gastrointestinal compositions |
| CN101248073A (zh) * | 2005-08-22 | 2008-08-20 | 塔加西普特公司 | 杂芳基-取代的二氮杂三环烷类、其制备方法及其应用 |
| EP1972629A1 (en) * | 2007-03-23 | 2008-09-24 | Mutabilis SA | New imidazolo-heteroaryl derivatives with antibacterial properties |
| FR2936798B1 (fr) | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
| FR2937034B1 (fr) * | 2008-10-10 | 2012-11-23 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens |
| AR090539A1 (es) * | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
| WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
-
2016
- 2016-04-01 KR KR1020177031671A patent/KR20170132316A/ko not_active Withdrawn
- 2016-04-01 BR BR112017020935A patent/BR112017020935A2/pt not_active Application Discontinuation
- 2016-04-01 JP JP2017551690A patent/JP2018510198A/ja active Pending
- 2016-04-01 RU RU2017134055A patent/RU2714197C2/ru active
- 2016-04-01 AU AU2016239861A patent/AU2016239861A1/en not_active Abandoned
- 2016-04-01 EP EP16713469.1A patent/EP3277277B1/en active Active
- 2016-04-01 TW TW105110646A patent/TW201639854A/zh unknown
- 2016-04-01 CA CA2980395A patent/CA2980395A1/en not_active Abandoned
- 2016-04-01 WO PCT/EP2016/057274 patent/WO2016156597A1/en not_active Ceased
- 2016-04-01 CN CN201680020682.XA patent/CN107438614B/zh active Active
- 2016-04-01 MX MX2017012545A patent/MX2017012545A/es unknown
- 2016-04-01 US US15/563,889 patent/US10501481B2/en active Active
-
2017
- 2017-09-20 ZA ZA201706348A patent/ZA201706348B/en unknown
- 2017-10-02 CL CL2017002482A patent/CL2017002482A1/es unknown
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10717737B2 (en) | 2014-02-13 | 2020-07-21 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US11155532B2 (en) | 2014-02-13 | 2021-10-26 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US11247992B2 (en) | 2014-02-13 | 2022-02-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US10968221B2 (en) | 2014-07-10 | 2021-04-06 | Incyte Corporation | Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US11401272B2 (en) | 2015-04-03 | 2022-08-02 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
| US11498900B2 (en) | 2015-08-12 | 2022-11-15 | Incyte Corporation | Salts of an LSD1 inhibitor |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| US11512064B2 (en) | 2018-08-31 | 2022-11-29 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017012545A (es) | 2018-09-28 |
| CN107438614A (zh) | 2017-12-05 |
| EP3277277B1 (en) | 2021-01-06 |
| AU2016239861A1 (en) | 2017-10-12 |
| US20180118765A1 (en) | 2018-05-03 |
| CN107438614B (zh) | 2020-01-31 |
| JP2018510198A (ja) | 2018-04-12 |
| CA2980395A1 (en) | 2016-10-06 |
| EP3277277A1 (en) | 2018-02-07 |
| RU2714197C2 (ru) | 2020-02-13 |
| KR20170132316A (ko) | 2017-12-01 |
| ZA201706348B (en) | 2019-11-27 |
| WO2016156597A1 (en) | 2016-10-06 |
| TW201639854A (zh) | 2016-11-16 |
| RU2017134055A3 (enExample) | 2019-08-30 |
| RU2017134055A (ru) | 2019-04-03 |
| US10501481B2 (en) | 2019-12-10 |
| BR112017020935A2 (pt) | 2018-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002482A1 (es) | Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas | |
| MX2023003461A (es) | Tratamiento de infeccion por clostridium difficile. | |
| CL2018001349A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CL2018001367A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CL2017003142A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2018000978A1 (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
| CL2017002451A1 (es) | Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CL2014001956A1 (es) | Compuestos derivados de beta-lactamicos sustituidos con amidina; metodo para su preparacion; medicamento que los comprende; y su uso para el tratamiento y/o profilaxis de infecciones bacterianas. | |
| MX381488B (es) | Indoles para su uso en la infección por el virus de la gripe. | |
| CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| CL2017002803A1 (es) | Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| CR20160433A (es) | Nuevos compuestos | |
| CL2015003019A1 (es) | Derivados biaromáticos antibacterianos | |
| CL2016000568A1 (es) | Compuestos derivados de 2h-indazol-2-il-n-hidroxi-2-metilsulfonil-2-metil-butanamida sustituidos o sus sales; sus composiciones farmacéuticas que los contiene y su uso para la prevención y/o tratamiento de infecciones bacterianas gram-negativas. | |
| EA201892822A1 (ru) | Новые антибактериальные соединения | |
| CO2019014647A2 (es) | Composiciones inmunogénicas | |
| CL2020001147A1 (es) | Compuestos antibacterianos | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. |